Christopher Marai
Stock Analyst at Nomura
(2.41)
# 2,500
Out of 5,141 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $7.42 | +12,838.01% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $82.76 | -60.13% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $5.71 | +1,476.18% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $336.19 | -77.99% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $3.49 | +358.45% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $192.03 | +104.13% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.30 | +2,515.38% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $18.88 | +1,118.22% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $19.69 | -39.06% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $9.02 | +110.64% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $3.90 | +1,002.56% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $7.42
Upside: +12,838.01%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $82.76
Upside: -60.13%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $5.71
Upside: +1,476.18%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $336.19
Upside: -77.99%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $3.49
Upside: +358.45%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $192.03
Upside: +104.13%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.30
Upside: +2,515.38%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $18.88
Upside: +1,118.22%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $19.69
Upside: -39.06%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $9.02
Upside: +110.64%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $3.90
Upside: +1,002.56%